Replies to post #149370 on Cytodyn Inc (CYDY)

[moneycrew]

The EIND's and the OLE's would have been stopped. The data is spectacular and the discussions are about logistics, labeling and importing from Samsung. Cytodyn is going to make history

[3X Charm]

Good or bad news, the data will be released when there is enough contextual evidence to not be misleading with any statements. The lack of PR demonstrates that adequate information has not yet been harvested from the analysis of the data.

[Bill_ENG]

Some physicians at 18 hospitals were doing just that . And while the trials are blinded , physicians are not blind. They can see a group of people getting shots and not know who got what.

However they will notice that some get better in a much more rapid fashion. Do you honestly think they will see someone get better more quickly than they are used to and surmise they got the placebo. uhhm no, they will think...he got the good stuff.

After the trial was no longer enrolling and they got the EINDs and then the Extension , they knew who was getting Leronlomab, because everybody getting a shot was getting Leronlomab.

After that it's just a shot and then observation.

Those doctors have a very good idea as to whether it works or not.

[Marksch1]

Perhaps you'd like a picture of the Leronlimab I was able to procure for my wife under EIND in mid December.

[bluefish1]

FDA granted Open Label Extension. They would not have done that if there was "no data that the drug works."

FDA allowed eINDs. That doesn't happen if there's "no data that the drug works." A Phase 3 HIV trial was completed that is "data that the drug works." There's a 2B/3 trial that was just completed for Covid. There's plenty of data.

Number of OLE and eIND is probably protected information. 1. for the patient/HIPAA. 2. for the company.

NP and Cytodyn may know. Doesn't mean we all get to know.

Company is in the process of disclosing data to the FDA, MHRA, and Health Canada. Go back and re-read the last PR.